埃索美拉唑治疗胃食管反流病临床对照观察评价

Clinical Control Observation and Evaluation of Treatment on Gastroesophageal Reflux Disease with Esomeprazole

目的评价埃索美拉唑(esomeprazole)治疗胃食管反流病(GERD)的临床疗效。方法随机将130例确诊的GERD患者分为两组,治疗组70例,给予埃索美拉唑40mg,口服,1次/天;对照组60例,给予兰索拉唑30mg,口服,1次/天,疗程均为8周。记录治疗后患者烧心、嗳气、反酸、胸骨后灼痛等症状积分改变,按症状积分改善及内镜检查结果对比分析疗效。结果治疗组GERD症状积分改善优于对照组,前2周,P<0.01,4周时P<0.05,食管黏膜损害愈合率,治疗组优于对照组分别为74.3%和61.7%,P<0.01,但总有效率分别为95.7%和93.3%,P>0.05,两组差异无显著统计学意义。结论埃索美拉唑是治疗胃食管反流病速效高效且安全的质子泵抑制剂(PPI)。

Objective To evaluate the clinical efficacy of Esomeprazole on treatment of gastroesophageal reflux disease （ GERD）. Methods 130 cases of definitely diagnosed GERD patients were randomly divided into 2 groups. 70 patients in treatment group were treated with Esomeprazole 40mg, PO, Qd; 60 patients in control group were treated with lansoprazole 30mg, PO, Qd. Both treatment courses were 8 weeks. The composite score change of patient symptoms, such as heartburn, belching, sour regurgitation and burning pain behind thoracic bone were recorded. The efficacy was analyzed by comparison of composite score improvement of symptoms as well as results of endoscope inspections. Results Composite score improvement of symptoms in treatment group was superior to that of control group （at first 2 weeks, P 〈 0. 01 ; at week 4, P 〈 0.05）. Healing rate of esophageal mucosa damage in treatment group was superior to that of control group,with 74.3% and 61.7% respectively （ P 〈 0. 01 ）. But the total effective rate of both groups was 95.7% and 93.3% respectively （ P 〉 0.05 ）. No significant statistical difference was found in both groups. Conclusion Esomeprazole is a quick - acting and safe proton pump inhibitor （PPI） with high - performance on treatment of GERD.